Anthony Heaney is an Endocrinology/Metabolic physician. OpenAlex indexes 204 publications with 9,916 citations (h-index 47); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Ucla Medical Plz
Los Angeles, CA 900951865
Telephone
310-825-7922Provider last certified this registry record 28 Aug 2020.
Clinical trials
- Rosiglitazone in Treating Patients With Pituitary Tumors
Sponsor: Jonsson Comprehensive Cancer Center
- Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
Sponsor: Jonsson Comprehensive Cancer Center
- Temozolomide in Treating Patients With Invasive Pituitary Tumors
Sponsor: Jonsson Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Corcept TherapeuticsProgram year202573 payments$102,031openpaymentsdata.cms.gov ↗
- RECORDATI_RARE_DISEASES_INC.Program year202544 payments$55,227openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202530 payments$41,228openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
9 NIH research awards on record, funded 2005–2026 per NIH RePORTER. The latest:
- Towards Safe and Efficacious Medical Therapy for Patients with Clinically Non-Functioning Pituitary Tumors
University of California Los Angeles
FY2026$475,401R01CA295582 - Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease (IND 168501 - 07/31/2023)
University of California Los Angeles
FY2026$417,737R01FD007548 - Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery
University of California Los Angeles
FY2025$356,850R01CA251930
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
The Journal of Clinical Endocrinology & Metabolism
2022 - Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2021 - Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?
Journal of the Endocrine Society
2021 - Corticotroph tumor progression after bilateral adrenalectomy (Nelson’s syndrome): systematic review and expert consensus recommendations
European Journal of Endocrinology
2021 - Multidisciplinary management of acromegaly: A consensus
Reviews in Endocrine and Metabolic Disorders
2020
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Jens J. Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Daniel J. Drucker
University of Toronto
Kenneth Cusi, MD
University of Florida College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”